Conciseness

The bulk is genuinely operational (tool call signatures, parameter shapes, verdict thresholds), but several sections explain textbook pharmacology Claude already knows: '~75% of drugs are metabolized by CYP enzymes... Inhibiting CYP3A4... causes dangerous drug-drug interactions', 'hERG potassium channel inhibition. Causes QT prolongation and fatal cardiac arrhythmia... (e.g., terfenadine, cisapride)', and the 'Why It Matters' table column restating Lipinski/Veber rationale. Not 2 because most of the content is skill-specific operational detail, not padding.

Actionability

Concrete, near copy-paste-ready guidance throughout: exact tool signatures ('ADMETAI_predict_toxicity(smiles=["<SMILES>"])', 'PubChem_get_compound_properties_by_CID(cid=<CID>)'), install command ('uv pip install tooluniverse[ml]'), explicit input formats (list vs string per tool), and numeric verdict thresholds. Not 5 because Phase 5 calls 'ChEMBL_get_molecule(chembl_id="<CHEMBL_ID>")' without ever explaining how to obtain the ChEMBL ID, and the Phase 1 identity record does not include it.

Workflow Clarity

A clearly sequenced 5-phase workflow (identity resolution -> physicochemical -> ADME -> toxicity -> scorecard) with explicit validation: 'LOOK UP DON'T GUESS: never assume SMILES, CID, or experimental LD50 values', per-phase fallbacks when ADMETAI is unavailable, guidance on expected console noise vs real errors, and a mandatory 10-item completeness checklist before reporting. This matches the level-5 anchor (explicit validation steps, feedback loops, checklist).

Progressive Disclosure

No bundle files exist (no references/, scripts/, or assets/), so everything lives inline in a ~305-line SKILL.md. Sections and headers are well-organized, but reference-grade material is inlined — the Phase 4 endpoint encyclopedics (AMES/DILI/hERG/ClinTox/LD50_Zhu explanations), the 9-row interpretation table, and the evidence-grading definitions are all content that belongs in a separate reference file per the 'some structure; content that should be separate is inline' anchor. Not 2 because the structure present is clear, not impenetrable.

Specificity

Names the domain ('Comprehensive ADMET profiling for drug candidates') and lists several concrete integrated capabilities ('ADMET-AI predictions, SwissADME drug-likeness, PubChemTox experimental toxicity, ChEMBL clinical data, Lipinski rule-of-five, and CYP interaction data'). Not 5 because the core action is a generic 'profiling' verb — concrete outputs like the pass/warn/fail scorecard are not mentioned; not 3 because multiple specific actions are named, matching the 'several specific actions; minor gaps' anchor.

Completeness

Explicitly answers both what ('Comprehensive ADMET profiling... Integrates ADMET-AI predictions, SwissADME drug-likeness, PubChemTox experimental toxicity, ChEMBL clinical data') and when ('Use for drug-likeness assessment, BBB penetration, bioavailability, hepatotoxicity prediction, ADME/PK profiling, or screening compound libraries before lab testing') with concrete trigger phrases — a direct match to the level-5 anchor. Third-person voice is used throughout.

Trigger Term Quality

'Use for drug-likeness assessment, BBB penetration, bioavailability, hepatotoxicity prediction, ADME/PK profiling, or screening compound libraries' gives good natural keyword coverage users would actually say. Not 5 because common variations are missing (e.g., 'toxicity prediction', 'LD50', 'safe compound', 'pharmacokinetics' spelled out); not 3 because coverage goes well beyond a couple of generic keywords.

Distinctiveness Conflict Risk

A clear niche (ADMET/drug-likeness profiling) with distinct triggers ('BBB penetration', 'hepatotoxicity prediction', 'ADME/PK profiling') that would not naturally fire for unrelated skills, matching the 'clear niche with distinct triggers; minimal conflict risk' anchor. Only negligible overlap risk with a hypothetical general toxicity-lookup skill.